Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...
Eli Lilly and Company announced data demonstrating more patients with moderately to severely active Crohn's disease treated with mirikizumab ...
20hon MSN
Chief Executive David Ricks told then-UK Health Secretary Victoria Atkins last December that the company’s new Alzheimer’s ...
Health Innovation Manchester and The University of Manchester has today (14 October 2024) announced a groundbreaking ...
DeepMind and Isomorphic Labs’ successes in drug discovery include its AlphaFold 2 AI system, which can accurately predict the structure of proteins, a discovery for which Hassabis and his DeepMind ...
Korea Joongang Daily on MSN2h
Weight-loss drug Wegovy to hit market on TuesdayWeight-loss drug Wegovy will go on sale in Korea on Tuesday, with the much-anticipated injectable drug available for order ...
Britain on Monday asked its antitrust regulator to make growth and investment a priority as the government sought to woo some ...
The future of the weight loss market might not revolve around GLP-1 drugs.
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
New estimates say that Medicare will spend tens of billions of dollars over nine years to cover weight-loss drugs.
Companies such as Google parent Alphabet, BlackRock and Brookfield Asset Management are set to be in attendance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback